CSRT.L - Consort Medical plc

LSE - LSE Delayed Price. Currency in GBp

Consort Medical plc

Breakspear Park
Suite B Breakspear Way
Hemel Hempstead HP2 4TZ
United Kingdom
44 14 4286 7920

IndustryMedical Devices
Full Time Employees2,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Jonathan M. GlennCEO & Exec. DirectorN/AN/A1969
Mr. Paul HayesCFO, Company Sec. & Exec. DirectorN/AN/A1967
Mr. Iain LindsayInterim Group Gen. CounselN/AN/AN/A
Ms. Lisa KingDirector of HRN/AN/AN/A
Dr. Keyvan DjamaraniManaging Director of BespakN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products. It also develops, formulates, and manufactures active pharmaceutical ingredients and finished dose drugs. Consort Medical plc was incorporated in 1946 and is based in Hemel Hempstead, the United Kingdom.

Corporate Governance

Consort Medical plc’s ISS Governance QualityScore as of May 1, 2018 is 7. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.